The ε4 allele of apolipoprotein E gene (APOE4) is the strongest genetic risk factor for Alzheimer’s disease (AD). Studies have indicated that APOE4 carriers develop vascular and metabolic dysfunctions several decades prior to the clinical symptom of dementia occurs. In this study, we used multi-modal MRI markers to investigate the effect of Rapamycin, a FDA approved drug, on genetically modified pre-symptomatic E4FAD mice, as a preventative therapeutic for AD. Cerebral blood flow and crucial brain metabolites detected by MR spectroscopy were restored in Rapamycin fed mice, consistent with lower BOLD responses, lower cerebrovascular-reactivity (CVR) and decreased Amyloid-beta deposition.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords